♥ HF Guideline NavigatorESC 2026

10

10 Non-cardiovascular comorbidities

Pages 65–69 · open in PDF

Recommendations in this section

  • Class IIaLevel B1Semaglutide or tirzepatide should be considered for patients with symptomatic HF, LVEF ≥ 45%, and BMI ≥ 30 kg/m², regardless of diabetes status, to reduce body weight, and improve exercise capacity and QoL.
  • Class IIbLevel CBariatric surgery may be considered in obese patients with HF and a BMI ≥ 35 kg/m² to reduce body weight when repetitive and structured lifestyle changes combined with weight-reducing medications do not result in maintained weight loss.
  • Class ILevel B1Intravenous iron supplementation is recommended in patients with symptomatic HFrEF and iron deficiency to alleviate HF symptoms and improve QoL.
  • Class IIaLevel B1Intravenous iron supplementation should be considered in patients with symptomatic HFrEF and iron deficiency to reduce the risk of HFH.
  • Class IIbLevel CAdaptive servo-ventilation may be considered in patients with HFrEF and sleep-disordered breathing with predominant obstructive sleep apnoea to improve sleep quality, health-related QoL and symptoms.
  • Class IIILevel AAdaptive servo-ventilation is not recommended in patients with HFrEF and sleep-disordered breathing with predominant central sleep apnoea because of an increased risk of CV and all-cause death.
  • Class IIaLevel CAssessment of anxiety, depression and frailty should be considered in patients with HF to support the development of personalized care plans and to identify factors that may contribute to adverse outcomes.
  • Class IIaLevel CInfluenza and pneumococcal vaccination should be considered in patients with HF to reduce the risk of pneumonia complications, hospitalization, and death.
  • Class IIILevel B2NSAIDs and COX-2 inhibitors are not recommended in patients with HF as they increase the risk of HF worsening and HFH.

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 65 · PDF

demonstrated favourable effects of the GLP-1 RA semaglutide and the dual GIP/GLP-1 RA tirzepatide in patients with HFpEF and obesity regardless of diabetes status, namely reduction of body weight, improvement of QoL, symptoms, and functional capacity (see Supplementary data online, Section S7.1).315–317 Pooled and secondary analyses of RCTs, and the recent SUMMIT trial, have also suggested a potential benefit of these drugs on HF events.317,819,820 Dedicated RCTs are needed to evaluate safety and efficacy of these drugs in patients with HFrEF and to assess long-term follow-up.821,822 In propensity score-matched cohort studies, bariatric surgery was associated with weight loss and a lower risk of all-cause and CV death, HFH, and AF as compared to medical therapy in patients with HF and a BMI ≥35 kg/m2, with consistent benefits observed among patients with HFrEF and HFpEF.823,824 Studies comparing bariatric surgery vs new anti-obesity medications are lacking, and the indications for bariatric surgery may change in the future. Recommendation Table 18 — Recommendations for obesity in patients with heart failure (see Evidence Tables 85 and 86) Recommendations

10. Non-cardiovascular comorbidities

Semaglutide or tirzepatide should be considered

and BMI ≥30 kg/m2, regardless of diabetes status, to reduce body weight, and improve

for patients with symptomatic HF, LVEF ≥45%,

exercise capacity and QoL.315–317,819,820,825 Bariatric surgery may be considered in obese patients with HF and a BMI ≥35 kg/m2 to reduce body weight when repetitive and structured lifestyle changes combined with weight-reducing medications do not result in maintained weight loss.823,824 BMI, body mass index; HF, heart failure; LVEF, left ventricular ejection fraction; QoL, quality of life. a Class of recommendation. b Level of evidence.

10.2. Diabetes Patients with HF who have T2DM have a poorer prognosis than patients who do not have T2DM.826–828 The diagnostic process and therapeutic approach to HF in patients with T2DM is the same as the population without T2DM. There is no evidence that the efficacy of FMT is altered by the presence of T2DM.241,829–833 60 The 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes dedicated a specific section to the treatment of diabetes in patients with HF.60 Sodium–glucose co-transporter 2 inhibitors have been investigated in different populations with diabetes, ranging from patients with ASCVD or multiple ASCVD risk factors to patients with established HF across the entire range of LVEF or recently hospitalized for WHF, with greater absolute risk reduction of clinical events in patients at higher risk.834 Thus, the use of

Obesity contributes to the development of well-known CV and HF risk factors like hypertension, diabetes, and dyslipidaemia. Obesity has direct adverse effects on cardiac structure and function, and is associated with the development of CVD, including HF.808 Patients with HF and obesity may have lower natriuretic peptide concentrations due to increased expression of clearance receptors, augmented peptide degradation by the adipose tissue,155 and underestimation of circulatory congestion.809 Peak oxygen consumption adjusted for body weight underestimates exercise capacity in obese patients, and an adjustment for lean body mass should be used for risk stratification pro-inflammatory.810 A stronger association between obesity and HFpEF rather than HFrEF has been described.778,811 Among patients with HFpEF, the obesity-related phenotype has a high prevalence (30%–40% in Europe and 60%–70% in North America).314,812 These patients display several pathophysiological mechanisms that differ from non-obese patients with HFpEF.813 An increase in adipocyte mass induces a state of systemic inflammation and a proinflammatory transformation of epicardial adipose tissue that may lead to fibrosis. The capacity of the left ventricle to dilate in response to an increase in blood volume is impaired, and thus, even modest degrees of volume overload may lead to cardiac overfilling and disproportionate increase in cardiac filling pressures.814 On average, patients with HFpEF and obesity are younger, experience worse HF signs and symptoms, poorer QoL, and worse functional capacity, than those without obesity.815,816 Weight-loss interventions in patients with HFpEF and obesity alleviate symptoms and may improve outcomes. Lifestyle interventions, such as caloric restriction, exercise, and patient education, have a significant impact on body weight and are recommended in all patients with HF.817,818 Recent RCTs

in 8%–11% patients with HF785–789 with similar790–794 or increased795,796 prevalence in patients with HFpEF compared with HFrEF. Poorer outcomes after stroke are observed in patients with HF with a 2.2–4.5 times higher rate of death compared with people without HF,782,783,797 as well as an increased rate of recurrent stroke.798 The risk of stroke in patients with HF seems independent of rhythm, with an annualized stroke risk of 2.0 per 100 patientyears in patients in sinus rhythm and 2.87 per 100 patient-years in patients with AF.799–802 However, RCTs failed to demonstrate a possible benefit of oral anticoagulation in patients with HFrEF in sinus rhythm.803–806 Thus, in the absence of AF, there is no evidence to recommend routine anticoagulation for stroke prevention in patients with HFrEF. Optimization of blood pressure, heart rate, and cardiac output immediately after a stroke is key to reducing the risk of DHF and improving outcomes. In patients already established on FMT, treatment with FMT should be maintained if possible and attention should be paid to dose modification in order to avoid both hypo- and hypertension as well as rebound tachycardia in patients in whom beta-blockers have been withdrawn.807 Following the acute phase, treatment of HF in patients with stroke does not differ from treatment in patients without stroke.

Page 66 · PDF

10.3. Chronic kidney disease Chronic kidney disease and HF frequently coexist.847 They share common risk factors and may develop simultaneously. CKD may lead to worsening of cardiac function and vice versa. The incidence of CKD is five-fold higher in patients with HF as compared with those without.848 About 30%–40% of individuals with chronic HF have CKD, with the highest proportions, up to 50%, in HFpEF.778,849,850 CKD is a major independent determinant of increased mortality and morbidity in HF.850 Albuminuria and low GFR are independently associated with an increased risk of major ASCVD, HF events, and CV death.61,851–854 The presence of CKD might have an impact on FMT optimization, and it is often cited as a reason for FMT under-utilization in clinical practice.855 Even in most patients with CKD the initiation of beta-blockers, ACE-Is/ARNIs/ARBs, SGLT2-Is, and MRAs is recommended.164 Several RCTs have shown that patients with HF and concomitant CKD are at higher risk of events as compared to those without CKD. However, no interaction between drug effects and kidney function was noted in subgroup analyses of these trials.242–245,309 Furthermore, the beneficial effects of FMT are similar, or even higher, irrespective of CKD.251,252,847,856–858 An evidence gap remains for the treatment of HF in patients with severe CKD as these patients were generally excluded from RCTs.

Worsening kidney function in patients with chronic HF is not necessarily associated with worse outcomes. For example, after initiation of ACE-Is/ARNIs/ARBs, MRAs or SGLT2-Is, an initial decrease in the glomerular filtration pressure may decrease GFR and increase serum creatinine. These changes are generally transient and occur despite improvement in patient outcomes and may delay long term deterioration of kidney function.243,250–253 Sacubitril–valsartan, compared with enalapril, led to a slower decline in kidney function, despite a slight increase in the UACR, and improved CV outcomes to a similar extent in patients with CKD vs other patients in the PARADIGM-HF trial.279 In a participant-level pooled analysis of the DAPA-HF and DELIVER trials, patients experiencing worsening of eGFR to <25 mL/min/1.73 m2 were at heightened risk for development of subsequent CV events. Continuation of dapagliflozin was associated with lower rates of the primary composite outcome.859 A prespecified secondary analysis of the FINEARTS-HF trial, in patients with HF and LVEF ≥40%, reported an acute decline in eGFR of −2.9 mL/min/1.73 m2 (95% CI −3.4 to −2.4) during the first 3 months on finerenone vs placebo.860 However, finerenone still reduced the risk of new-onset micro- and macroalbuminuria by 24% and 38%, respectively.860 Thus, a transient decrease in kidney function after the initiation of ACE-Is/ARNIs/ARBs and MRAs or SGLT2-Is should not prompt their interruption. An increase in serum creatinine of <50% above baseline, as long as eGFR remains >15 mL/ min/1.73 m2, is considered acceptable. Notably, in patients with HFpEF, semaglutide and tirzepatide may acutely reduce eGFR; however, they exhibit a long-term protective effect on kidney function.861,862 Chronic kidney disease is highly prevalent in patients with DHF. Worsening or improvement of kidney function occurs commonly, affecting about 30%–50% of patients admitted with HF.273 Adverse CV outcomes are observed in patients with worsening kidney function and poor diuretic response, but not in patients with good diuretic response.506,863 Data from the STRONG-HF trial showed that a decrease in eGFR within 1 week after discharge was associated with more evidence of congestion and with an increased incidence of HF readmissions.864 Conversely, worsening kidney function is not associated with poor outcomes in the context of successful decongestion.506,863 For further details refer to the 2026 ESC Guidelines on cardiovascular disease and chronic kidney disease.122

10.4. Iron deficiency and anaemia Iron deficiency and anaemia are common in patients with HF and are associated with reduced functional capacity, and worse QoL and prognosis independently of each other.778,865–868 Iron deficiency is slightly more prevalent in patients with HFpEF than in patients with HFrEF.865,869 In patients with HF, ID has been defined as either ferritin <100 ng/mL, or ferritin 100–299 ng/mL with TSAT <20%. This definition has been adopted by the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure3 and the 2023 Focused Update of the 2021 ESC Guidelines for the

SGLT2-Is is recommended in all patients with HF and T2DM, independently of glycated haemoglobin levels or other concomitant glucose-lowering agents. SGLT2-Is are generally well tolerated, although they may cause urinary infections and genital fungal infections as vulvovaginitis and balanitis with a prevalence of up to 6.9% in women and 4.8% in men. They are not indicated in patients with type 1 diabetes mellitus due to the risk of diabetic ketoacidosis (reported incidence of 2%– 3%).835,836 Semaglutide or tirzepatide should be added if not contraindicated in patients with HFpEF and T2DM, especially if they are also obese.316,317 Metformin, despite its long history as first-line treatment of T2DM, has no dedicated CV outcome trials to assess its safety or efficacy; observational studies reported a lower risk of death or HFH in patients with HF when compared with insulin and sulfonylureas.837–839 Metformin is not recommended in patients with an eGFR <30 mL/min/1.73 m2 or hepatic impairment because of the risk of lactic acidosis. In the context of T2DM, insulin glargine and insulin degludec have been evaluated in specific CV outcome trials, demonstrating a neutral effect on incident HF in patients with diabetes.840–842 In post-hoc analyses of RCTs and retrospective registries, use of insulin was associated with poorer outcomes among patients with HF. Thus, if insulin is needed in a patient with HF, patients should be monitored for WHF after initiation of treatment.843,844 The dipeptidyl peptidase-4 inhibitor saxagliptin and thiazolidinediones (glitazones) have been associated with an approximately 30% increased risk of HFH and, thus, are contraindicated in patients with HF.845,846 No consistent data are available for the use of sulphonylureas in patients with HF.60

Page 67 · PDF

Recommendation Table 19 — Recommendations for iron deficiency in patients with heart failure (see Evidence Tables 87 and 88) Recommendations Intravenous iron supplementation is recommended in patients with symptomatic HFrEF and iron deficiency to alleviate HF

Intravenous iron supplementation should be considered in patients with symptomatic HFrEF and iron deficiency to reduce the risk of 872–874,879,881,885,886,888

HF, heart failure; HFH, heart failure hospitalization; HFrEF, heart failure with reduced ejection fraction; QoL, quality of life. a Class of recommendation. b Level of evidence.

10.5. Cancer In patients with cancer, HF may occur as a result of the interactions between cancer therapy, cancer itself, and/or patients’ CV backgrounds (risk factors and coexisting CVD). Current cancer treatments may cause HF through direct cardiotoxic effects, or indirectly, favouring the occurrence of pathological conditions predisposing to HF, such as volume overload from i.v. infusions and corticosteroids, myocarditis, myocardial ischaemia, systemic or pulmonary hypertension, thromboembolism, arrhythmias, or valve disease.6,889,890 The definition of symptomatic and asymptomatic cancer therapy-related cardiac dysfunction is reported in Supplementary data online, Table S21. Cancer drugs causing HF are reported in Supplementary data online, Table S22. In patients who develop symptomatic HF during cancer therapy, FMT is recommended, regardless of LVEF.6 Discontinuation vs continuation of cardiotoxic drugs should be discussed by a multidisciplinary team. Severity of cancer therapy-related cardiac dysfunction guides the decision.6,891 Initiation of FMT for HFrEF is recommended in patients with asymptomatic moderate-to-severe cancer therapy-related cardiac dysfunction and should be considered in asymptomatic patients with mild presentations. For details regarding CV toxicity risk assessment process, diagnostic work-up, follow-up procedures, and therapeutic management of cardiotoxicity, we refer to the 2022 ESC Guidelines on cardio-oncology.6

10.6. Lung disease and sleep-disordered breathing Chronic obstructive pulmonary disease is common among patients with HF.892–894 Due to the overlap in symptoms and signs, the differentiation between HF and COPD may be difficult.895 Chronic obstructive pulmonary disease significantly impacts on symptoms and QoL, has been associated with HF undertreatment, and negatively influences prognosis of HF.893,896 Treatment of HF is generally well tolerated in COPD. The use of cardioselective beta-blockers (bisoprolol, metoprolol succinate, or nebivolol) should be preferred. In patients with asthma,

symptoms and improve QoL.875–879

diagnosis and treatment of acute and chronic heart failure,5 and has been used in almost all recent trials assessing the effects of i.v. iron supplementation in patients with HF and ID. However, it has recently been recognized that in patients with HF this definition does not reliably identify patients with absolute or functional ID. The current definition of ID may include patients with TSATs (≥20%) and serum ferritin levels (20– 100 mg/L) in the normal range, who are probably not iron deficient, exhibit a better prognosis, and might not respond to i.v. iron therapy.870 Moreover, serum ferritin levels are highly sensitive to inflammation and oxidative stress. Thus, an alternative definition of ID—TSAT <20%—has been proposed, mainly based on evidence from explorative analyses and meta-analyses of RCTs. A TSAT <20% has higher sensitivity and specificity compared with the previous definition of ID and is associated with higher mortality rates, independently of HF phenotype.869–871 Moreover, some meta-analyses of large RCTs reported that lower TSAT values better identify patients that will respond favourably to i.v. iron supplementation.872–874 The Task Force supports the use of this most recent definition of ID in patients with HF and recognizes the need for new trials investigating the efficacy of i.v. iron supplementation in patients with HF and ID as defined by TSAT <20%. Several trials, including AFFIRM-AHF,496 CONFIRM-HF,875 FAIR-HF,876,877 EFFECT-HF,878 and IRONMAN879 (where ID was defined as either ferritin <100 ng/mL, or ferritin 100– 299 ng/mL with TSAT <20%), have demonstrated that iron supplementation with i.v. ferric carboxymaltose is safe and effective in improving symptoms and QoL in patients with HF and LVEF <40%–45%. Thus, i.v. iron supplementation is recommended in patients with symptomatic HFrEF and ID to alleviate HF symptoms and improve QoL. Data in patients with HFpEF are scarce.880 The prognostic benefit of i.v. iron supplementation in patients with HF has been investigated in several RCTs and meta-analyses (see Supplementary data online, Section S7. 2).496,872,873,879,881–886 Given the conflicting results of major RCTs, the position of the Task Force is that evidence regarding the benefits of i.v. iron supplementation on strong endpoints is not conclusive. This is primarily due to the use of the old definition of ID as an enrolment criterion in almost all trials, the heterogeneity of RCTs in terms of enrolled populations as well as of i.v. iron doses and timing of administration and that some major RCTs were affected by the coronavirus disease 2019 pandemic. Thus, i.v. iron supplementation with ferric carboxymaltose or ferric derisomaltose should be considered in patients with symptomatic HFrEF and ID to reduce the risk of HFH, taking into account that patients with TSAT <20% might benefit most. Further trials using TSAT <20%, or other criteria that do not rely on ferritin levels as inclusion criteria, are warranted. In patients with HFrEF and mild to moderate anaemia enrolled in the RED-HF trial,887 darbepoetin-alpha failed to reduce all-cause death or HFH and showed an increased risk of thromboembolic events. Thus, erythropoietin-stimulating agents should be avoided for the treatment of anaemia related to HF.

Page 68 · PDF

10.7. Anxiety, depression, and cognitive impairment

these medications require more caution and should be started at low doses after consideration of the risks and benefits, with close monitoring for signs of airway obstruction, and appropriate supervision.897 Chronic obstructive pulmonary disease exacerbations should not be a cause of beta-blocker discontinuation.898 Inhaled corticosteroids and beta-adrenergic agonists have not been specifically studied in patients with HF; however, they do not seem to increase CV risk.899,900 In addition, appropriate management of COPD can improve cardiac function.901 Sleep-disordered breathing is found in over one-third of patients with HF and is even more prevalent in DHF. Sleepdisordered breathing includes OSA, central sleep apnoea (CSA), and mixed disease. SDB negatively impacts disease progression and prognosis.902,903 Patients with a suspicion of SDB should be referred for overnight polysomnography to definitively diagnose SDB, and to document the predominant type of sleep apnoea (central vs obstructive).902 The therapeutic approach to SDB includes the correction of underlying causes, when identified. The use of adaptive servo-ventilation (ASV) in patients with HFrEF and predominantly CSA is not recommended, based on the results of the SERVE-HF trial,904 which showed an increase in both all-cause and CV death in patients with chronic HF, LVEF ≤45%, and SDB with predominant CSA.904 The ADVENT-HF trial randomized 731 patients with HF, LVEF ≤45%, and coexisting SDB, mostly OSA (73%) to standard optimal treatment alone or standard optimal treatment and ASV (1:1). Over a mean follow-up period of 3.6 years, ASV had a neutral effect on the primary composite outcome (the cumulative incidence of all-cause death, first CV hospitalization, new-onset AF/flutter, and delivery of an appropriate ICD shock).905 However, ASV improved sleep quality and structure, health-related QoL, and symptoms of patients with SDB.905 Thus, in patients with SDB and predominant OSA, nocturnal hypoxaemia can be treated with nocturnal oxygen supplementation, continuous positive airway pressure (CPAP), bilevel positive airway pressure, and ASV. When SDB is caused by CSA, implantable phrenic nerve stimulation was found to be safe and effective in reducing the apnoea–hypopnoea index in a small RCT.906–908

10.8. Frailty Frailty is defined as a multidimensional, dynamic, and potentially reversible state, related to, but independent of, age, that makes individuals more vulnerable to the effects of stressors and at increased risk of poor outcomes. A score assessing frailty including four domains (clinical, functional, psychocognitive, and social) has recently been proposed.918 The presence of frailty might have an impact on disease management and is associated with higher rates of death and hospitalizations, and reduced health-related QoL, regardless of which tool was used to assess frailty.919–923 In patients with HF, frailty is particularly prevalent in older adults. When frailty is suspected or identified, a multidisciplinary approach to facilitate an individualized management is warranted.918,922,924

Recommendation Table 20 — Recommendations for lung disease and sleep-disordered breathing (see Evidence Table 89) Recommendations

Anxiety and depression are common findings in patients affected by chronic and disabling conditions, such as HF, and need to be promptly identified to minimize psychological distress and its negative consequences.909 Depression affects 20% of patients with HF, and it may affect adherence to FMT. Its prevalence is higher in women, and it is associated with worse clinical status and poorer prognosis.910–912 The diagnosis of depression typically relies on standardized questionnaires and clinical interviews. Symptom overlap between HF and depression can complicate diagnosis, as both conditions may present with cognitive issues (e.g. difficulty concentrating) and physical symptoms (e.g. fatigue). Several validated questionnaires are available for screening clinically significant depressive symptoms911 (see Supplementary data online, Section S7.4, Table S23). Cognitive impairment in these patients has been reported.911,913 However, there is still no consensus on the best therapy for patients with HF and depression. Cognitive behavioural therapy has demonstrated significant favourable long-term (4–9 months) reduction of anxiety and depression and improvement in QoL compared with nontreated patients.914,915 The safety of sertraline and escitalopram has been demonstrated, although without a significant reduction in depression compared with placebo.916,917 Tricyclic antidepressants should be avoided for the treatment of depression in HF as they may cause hypotension, WHF, and arrhythmias.911,912

Adaptive servo-ventilation may be considered in

Recommendation Table 21 — Recommendations for anxiety, depression, and frailty (see Evidence Tables 90 and 91)

apnoea to improve sleep quality, health-related QoL and symptoms.905

Adaptive servo-ventilation is not recommended III

apnoea because of an increased risk of CV and all-cause death.

Assessment of anxiety, depression and frailty

CV, cardiovascular; HFrEF, heart failure with reduced ejection fraction; QoL, quality of life. a Class of recommendation. b Level of evidence.

in patients with HFrEF and sleep-disordered breathing with predominant central sleep

should be considered in patients with HF to support the development of personalized care plans and to identify factors that may contribute to adverse outcomes.909,914,915,920,923 HF, heart failure. a Class of recommendation. b Level of evidence.

patients with HFrEF and sleep-disordered breathing with predominant obstructive sleep

Page 69 · PDF

10.9. Other non-cardiovascular comorbidities Infections may cause WHF and can precipitate HFH.925,926 Infections should ideally be prevented or, if present, promptly recognized and treated to avoid disease progression.927–930 Influenza vaccination is associated with a reduced risk of pneumonia and all-cause death in patients with HF.931–936 Thus, influenza and pneumococcal vaccination should be considered in all patients with HF in order to reduce the risk of infection-related complications.935 Thyroid dysfunction can cause changes in cardiac function and structure and may precipitate DHF.937,938 Assessment of thyroid function is recommended in patients with de novo HF or DHF and should be regularly assessed during follow-up of patients with HF. Treatment of thyroid dysfunction should be guided by endocrine guidelines.939–942 Hyperuricaemia and consequent gout attacks can be frequent in patients with HF, mainly caused or precipitated by diuretic treatment.943,944 Allopurinol is recommended as the first choice to chronically reduce uric acid levels in patients with HF,945 whereas colchicine can be used for acute gout attacks. Non-steroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors are not recommended in patients with HF because they may precipitate decompensation and worsen kidney function.942,946–948 Heart failure and erectile dysfunction frequently coexist.949,950 Cardioselective beta-blockers should be preferred in patients with HF and erectile dysfunction, mainly bisoprolol and nebivolol, started at the lowest doses.897 In the presence of erectile dysfunction symptoms, phosphodiesterase-V inhibitors are generally safe and can be considered in patients who are compensated,951 avoiding their concomitant use with nitrates.952 Recommendation Table 22 — Recommendations for other non-cardiovascular comorbidities (see Evidence Tables 92 and 93)

Influenza and pneumococcal vaccination should be considered in patients with HF to reduce the risk of pneumonia complications,

Recommendation Table 23 — Recommendations for the multidisciplinary management of heart failure (see Evidence Tables 94–96)

hospitalization, and death.

NSAIDs and COX-2 inhibitors are not recommended in patients with HF as they increase the risk of HF worsening and

HFH.942,946–948 COX-2, cyclooxygenase-2; HF, heart failure; HFH, heart failure hospitalization; NSAID, non-steroidal anti-inflammatory drug. a Class of recommendation. b Level of evidence.

11. Multidisciplinary team management, long-term follow-up, and patient care 11.1. Multidisciplinary management of heart failure Multidisciplinary care for HF combines the expertise of various professionals to provide integrated, patient-centred care that

Recommendations A multidisciplinary HF management programme is recommended in patients with HF to reduce the risk of HFH and

death.964–967 HF education and self-management strategies in patients with HF are recommended to reduce the risk of HFH or death.977 Multidisciplinary interventions to improve adherence, including assessment of health literacy and polypharmacy review, are recommended in patients with HF to reduce the risk of hospitalization and death.978–981 HF, heart failure; HFH, heart failure hospitalization. a Class of recommendation. b Level of evidence.

improves both clinical outcomes and QoL for patients (Figure 21). Access to healthcare professionals with awareness of HF and expertise in its diagnosis and management is essential for early detection and better outcomes. Multidisciplinary HF care involves generalist and specialist healthcare professionals,955 including cardiologists, cardiothoracic surgeons, specialist nurses, pharmacists, and physiologists (Figure 21) (see Supplementary data online, Section S8.1).17,956–963 Management by an HF multidisciplinary team (HF-MDT) across outpatient and inpatient settings improves outcomes for people with HF.962,964–967 The literature evaluates various methods of delivering HF management programmes enabling local HF services to design services tailored to their HF-MDT and the structure of their healthcare system. A meta-analysis of 16 RCTs with 3999 eligible patients evaluating the benefits of multidisciplinary HF clinics compared with usual care demonstrated a reduction in HFH.967 A meta-analysis of eight RCTs with 1764 patients indicated that multidisciplinary teams may have the potential to reduce death, although a definitive RCT is needed.964 The benefits were more evident in patients with a recent emergency department presentation or HFH.966 Other methods of delivery, including home visits and transitional care models, are given in Supplementary data online, Section S8.1.145,962,965,968–972 Healthcare professionals involved in the management of HF, whether specialist or generalist, should be equipped with the knowledge required to effectively assess and manage HF through appropriate education and training.958,973,974 Malnutrition has been associated with worse prognosis in patients with HF.738 Thus, nutritional assessment and dietary interventions can be useful.588,589 No evidence supports fluid restriction in chronic HF.975,976